LIOMETACEN ® is a drug based on indomethacin meglumine
THERAPEUTIC GROUP: Non-steroidal anti-inflammatory and antirheumatic drugs
Indications LIOMETACEN ® Indomethacin
LIOMETACEN ® is indicated in the treatment of acute pain on an inflammatory basis of the musculoskeletal system.
Mechanism of action LIOMETACEN ® Indomethacin
LIOMETACEN ® is a drug based on indomethacin, an active ingredient derived from arylacetic acid and counted among non-steroidal anti-inflammatory drugs.
The characteristic efficacy of LIOMETACEN ® in the treatment of acute pain affecting the musculoskeletal system for both rheumatic and post-traumatic pathologies is due to the particular pharmacokinetic properties of this medicine, which allow its active ingredient, once administered for intramuscularly, to reach the plasma peak in just 30 minutes, carrying out immediately a significant therapeutic action.
The latter, as with all other non-steroidal anti-inflammatory drugs, is supported by the ability of indomethacin to inhibit an enzymatic class known as cyclooxygenase, whose activation, particularly intense following various harmful stimuli, allows the transformation of membrane phospholipids such as arachidonic acid into chemical mediators with vasopermeabilizing, chemotactic and algogenic activity, known as prostaglandins.
The possibility of reducing the local presence of these molecules therefore translates into a reduction of the inflammatory insult of a harmful and painful nature, which is therefore accompanied by the various inflammatory states of both traumatic and rheumatic origin.
At the end of its action, indomethacin, following hepatic glucuronation, is eliminated mainly through the urine.
Studies carried out and clinical efficacy
1. THE "EFFECTIVENESS OF" INDOMETHACIN IN PREMATURE BIRTHS
Pediatr Int. 2012 Feb 20.
Effects of Prophylactic Indomethacin on Renal and Intestinal Blood Flows in Premature Infants.
Maruyama K, Fujiu T.
Interesting study that demonstrates how the use of low doses of indomethacin in premature babies can, by taking advantage of the vasodilatory properties typical of NSAIDs, favor the normal vascularization of the kidney and intestine, limiting the onset of potential complications.
2 .L "INDOMETHACIN IN THE TREATMENT OF HEADACHE AND HEADACHE
CNS Drugs. 2011 Apr; 25: 343-58.
Indomethacin / prochlorperazine / caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.
Hoy SM, Scott LJ.
Recent study that demonstrates how the assumption of indomethacin, together with that of prochlorperazine and caffeine, can represent a valid therapeutic option in the treatment of acute migraine and tension-type headache.
3. INDOMETHACIN IN ORTHOPEDIC PRACTICE
Strahlenther Onkol. 2009 Aug; 185: 500-5. Epub 2009 Aug 4.
Combined radiotherapy and indomethacin for the prevention of heterotopic ossification after total hip arthroplasty.
Pakos EE, Stafilas KS, Tsekeris PG, Politis AN, Mitsionis G, Xenakis TA.
Study that demonstrates how the combined treatment of radiotherapy and indomethacin can be more effective in preventing heterotopic ossification, as a complication of total hip replacement surgery.
Method of use and dosage
LIOMETACEN ®
Powder and solvent for solution for injection of 25 - 50 mg of indomethacin.
The treatment of acute painful states involves a dosage schedule consisting of an attack phase characterized by the deep intramuscular administration of 1 or 2 ampoules of LIOMETACEN ® per day, depending on the medical indications and the severity of the pathological picture.
Intramuscular inoculation should preferably take place at the level of the upper-outer quadrant of the buttock.
The use of LIOMETACEN ® intravenously is indicated only in hospital practice.
Warnings LIOMETACEN ® Indomethacin
The use of LIOMETACEN ® must necessarily take place under strict medical supervision, given the numerous side effects associated with systemic therapy with non-steroidal anti-inflammatory drugs.
In order to limit the incidence of possible adverse reactions, it would be advisable to start treatment with the lowest effective dose, limiting the intake of the medicine for the shortest possible time.
Particular caution must be reserved for atopic patients suffering from hepatic, renal, gastro-intestinal and cardiovascular diseases, given the ability of indomethacin to aggravate the clinical course of pathological pictures already present as well as increase the incidence of new adverse events.
If unexpected reactions or any exacerbations of the pathologies already present appear, the patient, after contacting his doctor, should evaluate the possibility of suspending the therapy in progress.
The presence in LIOMETACEN ® of excipients with allergenic power, could increase the incidence of side effects linked to hypersensitivity reactions in predisposed subjects, especially during the first month of treatment.
PREGNANCY AND BREASTFEEDING
Different studies show how the intake of non-steroidal anti-inflammatory drugs such as indomethacin during pregnancy, especially in the third trimester, can cause a significant increase in the risk of fetal malformations, with such significant alterations in renal and cardiopulmonary function, as to induce spontaneous abortions.
In addition to the fetal side effects, there are also those affecting the mother, characterized by an increased risk of haemorrhage and complications at the time of delivery, linked to the reduction in the frequency and intensity of uterine contractions.
Interactions
During therapy with indomethacin it is necessary to consider all possible drug interactions capable of altering the normal pharmacokinetic profile of the active ingredient, varying both its therapeutic efficacy and its safety profile.
For this reason it would be necessary to avoid the simultaneous intake of indomethacin with:
- Oral anticoagulants and serotonin reuptake inhibitors, known to have an increased risk of bleeding;
- Diuretics, ACE inhibitors, angiotensin II antagonists, methotrexate and cyclosporins, given the increase in the possible toxic effects of indomethacin especially on the kidney and liver;
- Non-steroidal and cortisone anti-inflammatory drugs, responsible for significant damage to the gastric mucosa;
- Antibiotics, the intake of which is often linked to a significant variation in the therapeutic profile of both drugs;
- Sulfonylureas, potentially dangerous for alterations in glucose homeostasis.
Contraindications LIOMETACEN ® Indomethacin
The intake of LIOMETACEN ® is contraindicated in case of hypersensitivity to the active substance or to one of its excipients, hypersensitivity to acetylsalicylic acid and other analgesics, nasal polyposis, asthma, bronchospasm, angioedema, peptic ulcer, history of intestinal bleeding, colitis ulcer disease, Crohn's disease or previous history of the same conditions, cerebrovascular bleeding, haemorrhagic diathesis or concomitant anticoagulant therapy, renal insufficiency and hepatic insufficiency.
Undesirable Effects - Side Effects
Indomethacin shares the same side effects with all other non-steroidal anti-inflammatory drugs, which currently represent one of the main complications associated with systemic NSAID therapy.
More precisely, prolonged use over time or carried out at particularly high doses of indomethacin, could lead to the onset of nausea, constipation, diarrhea, epigastric pain, gastritis, ulcers and, in the most serious cases, haemorrhages, hepatotoxicity and liver failure, pulmonary edema and dyspnoea. , hypertension, vasodilation, increased brain and cardiovascular accidents, angioedema, rash, increased sweating, urticaria and bullous reactions, impaired renal function, headache, dizziness, vertigo, hyperkinesia and altered taste.
To the aforementioned adverse reactions it is necessary to add those deriving from possible hypersensitivity reactions to the drug or to one of its excipients, given the enteral route of administration.
Note
LIOMETACEN ® can only be sold with a medical prescription.
The information on LIOMETACEN ® Indomethacin published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
